Benzinga | Jul 30, 2020 09:55AM EDT

Evelo Biosciences Earlier Reported Q2 EPS $(0.63) Beats $(0.78) Estimate

Evelo Biosciences (NASDAQ:EVLO) reported quarterly losses of $(0.63) per share which beat the analyst consensus estimate of $(0.78) by 19.23 percent. This is a 3.08 percent increase over losses of $(0.65) per share from the same period last year.